1. Home
  2. SII vs ANIP Comparison

SII vs ANIP Comparison

Compare SII & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SII
  • ANIP
  • Stock Information
  • Founded
  • SII 2008
  • ANIP 2001
  • Country
  • SII Canada
  • ANIP United States
  • Employees
  • SII N/A
  • ANIP 897
  • Industry
  • SII Finance: Consumer Services
  • ANIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • SII Finance
  • ANIP Health Care
  • Exchange
  • SII Nasdaq
  • ANIP Nasdaq
  • Market Cap
  • SII 2.1B
  • ANIP 2.0B
  • IPO Year
  • SII N/A
  • ANIP N/A
  • Fundamental
  • Price
  • SII $81.91
  • ANIP $94.10
  • Analyst Decision
  • SII
  • ANIP Strong Buy
  • Analyst Count
  • SII 0
  • ANIP 7
  • Target Price
  • SII N/A
  • ANIP $99.14
  • AVG Volume (30 Days)
  • SII 178.7K
  • ANIP 319.6K
  • Earning Date
  • SII 11-05-2025
  • ANIP 11-07-2025
  • Dividend Yield
  • SII 1.47%
  • ANIP N/A
  • EPS Growth
  • SII 22.12
  • ANIP N/A
  • EPS
  • SII 1.94
  • ANIP N/A
  • Revenue
  • SII $197,660,000.00
  • ANIP $747,399,000.00
  • Revenue This Year
  • SII $22.82
  • ANIP $39.99
  • Revenue Next Year
  • SII $2.37
  • ANIP $9.57
  • P/E Ratio
  • SII $42.13
  • ANIP N/A
  • Revenue Growth
  • SII 20.02
  • ANIP 38.68
  • 52 Week Low
  • SII $39.33
  • ANIP $52.50
  • 52 Week High
  • SII $89.58
  • ANIP $99.50
  • Technical
  • Relative Strength Index (RSI)
  • SII 51.84
  • ANIP 55.26
  • Support Level
  • SII $79.83
  • ANIP $90.06
  • Resistance Level
  • SII $83.77
  • ANIP $93.80
  • Average True Range (ATR)
  • SII 2.47
  • ANIP 3.07
  • MACD
  • SII -0.76
  • ANIP -0.10
  • Stochastic Oscillator
  • SII 29.18
  • ANIP 64.36

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: